Literature DB >> 28248642

Virtual EPID standard phantom audit (VESPA) for remote IMRT and VMAT credentialing.

Narges Miri1, Joerg Lehmann, Kimberley Legge, Philip Vial, Peter B Greer.   

Abstract

A virtual EPID standard phantom audit (VESPA) has been implemented for remote auditing in support of facility credentialing for clinical trials using IMRT and VMAT. VESPA is based on published methods and a clinically established IMRT QA procedure, here extended to multi-vendor equipment. Facilities are provided with comprehensive instructions and CT datasets to create treatment plans. They deliver the treatment directly to their EPID without any phantom or couch in the beam. In addition, they deliver a set of simple calibration fields per instructions. Collected EPID images are uploaded electronically. In the analysis, the dose is projected back into a virtual cylindrical phantom. 3D gamma analysis is performed. 2D dose planes and linear dose profiles are provided and can be considered when needed for clarification. In addition, using a virtual flat-phantom, 2D field-by-field or arc-by-arc gamma analyses are performed. Pilot facilities covering a range of planning and delivery systems have performed data acquisition and upload successfully. Advantages of VESPA are (1) fast turnaround mainly driven by the facility's capability of providing the requested EPID images, (2) the possibility for facilities performing the audit in parallel, as there is no need to wait for a phantom, (3) simple and efficient credentialing for international facilities, (4) a large set of data points, and (5) a reduced impact on resources and environment as there is no need to transport heavy phantoms or audit staff. Limitations of the current implementation of VESPA for trials credentialing are that it does not provide absolute dosimetry, therefore a Level I audit is still required, and that it relies on correctly delivered open calibration fields, which are used for system calibration. The implemented EPID based IMRT and VMAT audit system promises to dramatically improve credentialing efficiency for clinical trials and wider applications.

Entities:  

Mesh:

Year:  2017        PMID: 28248642     DOI: 10.1088/1361-6560/aa63df

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  5 in total

1.  An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group-Radiation Therapy Study Group.

Authors:  Teiji Nishio; Mitsuhiro Nakamura; Hiroyuki Okamoto; Satoshi Kito; Toshiyuki Minemura; Shuichi Ozawa; Yu Kumazaki; Masayori Ishikawa; Naoki Tohyama; Masahiko Kurooka; Takeo Nakashima; Hidetoshi Shimizu; Ryusuke Suzuki; Satoshi Ishikura; Yasumasa Nishimura
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

Review 2.  Novel methodologies for dosimetry audits: Adapting to advanced radiotherapy techniques.

Authors:  Marlies Pasler; Victor Hernandez; Núria Jornet; Catharine H Clark
Journal:  Phys Imaging Radiat Oncol       Date:  2018-03-19

3.  Dosimetric end-to-end tests in a national audit of 3D conformal radiotherapy.

Authors:  Joerg Lehmann; Andrew Alves; Leon Dunn; Maddison Shaw; John Kenny; Stephanie Keehan; Jeremy Supple; Francis Gibbons; Sophie Manktelow; Chris Oliver; Tomas Kron; Ivan Williams; Jessica Lye
Journal:  Phys Imaging Radiat Oncol       Date:  2018-04-24

4.  Verification of stereotactic radiosurgery plans for multiple brain metastases using a virtual phantom-based procedure.

Authors:  Juan-Francisco Calvo-Ortega; Peter B Greer; Sandra Moragues-Femenía; Miguel Pozo-Massó; Joan Casals-Farran
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29

5.  A remote EPID-based dosimetric TPS-planned audit of centers for clinical trials: outcomes and analysis of contributing factors.

Authors:  Narges Miri; Kimberley Legge; Kim Colyvas; Joerg Lehmann; Philip Vial; Alisha Moore; Monica Harris; Peter B Greer
Journal:  Radiat Oncol       Date:  2018-09-17       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.